MorphoSys Granted Further Patent on its Core Antibody Technology in Japan
MARTINSRIED, GERMANY--(Marketwire - March 15, 2010) -
MorphoSys AG / MorphoSys Granted Further Patent on its Core Antibody Technology in Japan processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that the Japanese Patent Office has granted a new patent providing extended protection for the Company's core technology HuCAL. The new patent (JP 4436457) covers the production and design of an antibody library based on phage display. Currently, the Company is prosecuting more than 35 different proprietary patent families worldwide, in addition to about the same number of patent families the Company is pursuing in cooperation with its partners.
"Important progress was made with our patent portfolio during 2009 and in the first quarter of 2010, including the issuance of the first Japanese patents covering our core proprietary technologies HuCAL and CysDisplay," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "Our growing patent estate in Asia complements our strong intellectual property portfolio around HuCAL in other key pharmaceutical markets."
MorphoSys's HuCAL libraries are collections of highly diverse, fully human synthetic antibodies, whose modular CDR designs facilitate systematic engineering of antibody properties. The Company's most advanced version of the technology, HuCAL PLATINUM, provides rapid access to fully human antibodies for use as research tools, diagnostics and therapeutics.
marketwire.com |
